JBIO earnings
Jade Biosciences Inc. (JBIO) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune DiseasesJADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201's high affinity binding and extended half-life enabled dose-dependent BAFF receptor occupancy and sustained B cell depletion in non-human primatesFirst-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026; potential for broad opportunity across multiple autoimmune diseases validated by BAFF-R biologyCompany to host conference call and webcast today at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia,
- Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA NephropathyPreclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and pharmacodynamic profile with deep and sustained IgA reductions and the potential to support convenient subcutaneous dosing every eight weeks or longer First-in-human trial expected to begin second half 2025; biomarker-rich interim data in healthy volunteers expected first-half 2026 to inform patient dose and schedule Company to host conference call and webcast today, June 9, 2025, at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, June
- Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association CongressSAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered